Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office has granted a Notice of Allowance to specialty pharmaceutical company AlphaRx for its pain drug candidate ARX8203.
Subscribe to our email newsletter
ARX8203 has showed positive and significant safety profile in GI toxicity studies compared with Diclofenac and Indomethacin, two very popular and currently marketed NSAIDs.
AlphaRx has developed three formulations using ARX8203, an injectable formulation for post-surgical pain, an oral capsule for chronic pain and an ophthalmic formulation for ocular inflammation.
In total, AlphaRx has eight further US patent applications pending in different stages of examination and it is confident that this is the first of many patents yet to receive allowance.